ABSTRACT The plasma tuberculosis drug activity (TDA) assay may be an alternative tool for therapeutic drug monitoring in resource-limited settings. In tuberculosis (TB) patients (n ϭ 30), TDA and plasma levels of first-line drugs were analyzed 2 h postdose, 2 weeks after treatment initiation. Patients with plasma levels of rifampin lower than 8 mg/liter had a significantly lower median TDA (1.40 versus 1.68, P ϭ 0.0013). TDA may be used to identify TB patients with suboptimal rifampin levels during TB treatment.
R
ecently, the maintenance of adequate plasma drug exposure during the treatment of tuberculosis (TB) by therapeutic drug monitoring (TDM) has been emphasized (1) (2) (3) . Studies have shown that 30 to 85% of TB patients have rifampin (RIF) plasma levels below the currently recommended cutoff (8 mg/liter), which may lead to drug resistance development and suboptimal treatment outcomes (4) (5) (6) (7) . Even though a new methodology such as liquid chromatography-mass spectrometry (LC-MS) combined with dried blood spot samples has made TDM more available (8) , such methods are rarely accessible in areas where TB is highly endemic. The plasma TB drug activity (TDA) assay, first reported in 2011 (9) , gives an indirect measurement of drug exposure based on the patient's plasma drug activity against Mycobacterium tuberculosis and could be used in laboratories with access to TB culture. Previously, a significant correlation was reported between TDA and drug levels of isoniazid (INH) and RIF (9) . TDA determination may be useful for TDM in settings lacking LC-MS, as emerging data suggest using higher RIF doses (5). Our aims were to investigate the analytical precision of the TDA assay and to determine whether it could be used as an indicator of plasma concentrations of rifampin.
Consenting adult patients starting first-line TB treatments at Linköping University Hospital and Karolinska University Hospital Solna, Sweden, were included in this study. The study was approved by the ethical committee of Linköping University (2012/197-31). The exclusion criteria were patients with multidrug-resistant TB or ongoing treatment for infectious diseases other than HIV. The definitions and treatments of pulmonary TB (PTB) and extrapulmonary TB were in accordance with WHO recommendations (10) . For drug concentration analysis and the TDA assay, 10 ml of blood was obtained after an overnight fast at week two, 2 h after the observed intake of the drugs, the time at which peak drug concentrations for RIF and INH are expected. The definitions of lower-than-recommended drug concentration levels for RIF (Ͻ8 mg/liter) and INH (Ͻ3 mg/liter) were based on clinical practice and previous studies (3, 11) , although these cutoffs are poorly validated against clinical outcomes (7) . The determinations of plasma concentrations of INH were performed using high-pressure liquid chromatography (Agilent 1100 HPLC-system; Agilent, Santa Clara, CA, USA) and those of RIF by LC-MS (Agilent, Santa Clara, CA, USA) at Karolinska University Laboratory. TDA was determined as previously described (9) . Briefly, M. tuberculosis H37Rv (ATCC 27294) equivalent to a 0.5 McFarland standard was diluted 1:10, washed and resuspended in 300 l phosphate-buffered saline, and incubated for 72 h at 37°C with 300 l patient plasma or 300 l antibiotic-free human control plasma in duplicates. After washing, the suspensions were incubated in a Bactec MGIT 960 instrument until the time to detection (TTD). TDA was calculated as the ratio of the TTD for H37Rv in the MGIT tube with patient plasma in relation to that in the tube with control plasma. In each experiment, control plasma samples (n ϭ 4 to 8) and plasma with 8 mg/liter RIF were analyzed to evaluate the assay precision (coefficient of variation [CV] ). The data are presented as medians and interquartile ranges (IQRs). Spearman's rank correlation, Mann-Whitney U, and Fisher's tests were used for comparisons, and a P value of Ͻ0.05 was considered statistically significant.
The median age of the patients was 32 years (IQR, 26 to 44 years), 60% (18/30) were female patients, and 60% (18/30) were from sub-Saharan Africa. No patient had an HIV infection, and 80% (24/30) of the study participants had PTB. There were no differences in RIF doses (median, 9.4 mg/kg; IQR, 8.2 to 10.1 mg/kg) between patients with plasma RIF concentrations higher than or lower than 8 mg/liter (P ϭ 0.82). The correlation between TDA and RIF levels at 2 h after drug intake was significant (r ϭ 0.54, P ϭ 0.002) (Fig. 1) , and TDA levels of Ͻ1.5 correlated with lower RIF levels (P Ͻ 0.001) (Fig. 2) . The median TDA was significantly lower in TB patients with RIF levels Ͻ8 mg/liter than in (Fig. 3) . In patients with INH levels of less than or greater than 3 mg/liter, the median TDA values were similar (1.64 [1.44 to 1.69] versus 1.52 [1.35 to 1.71], respectively, P ϭ 0.64), which was also the case for pyrazinamide (PZA) and ethambutol (EMB) (data not shown). The median TTDs for control plasma (n ϭ 30) and the positive control (n ϭ 14) were 239.5 h (172 to 264 h) and 412.5 h (323 to 446 h), respectively. The CV for intraassay variability was 9.6% for the negative controls (n ϭ 8), whereas the CVs for interassay variability were 23.0% for the negative (n ϭ 30) and 18.2% for the positive (n ϭ 14) controls.
We observed an association between TDA and levels of RIF, whereas the effects of PZA and EMB were negligible, similar to a previous study (9) . The correlation between exact levels of TDA and RIF was significant but with a rather low correlation coefficient. However, we found a highly significant relation between clinically used cutoff levels for low plasma RIF concentrations (Ͻ8 mg/liter) and low TDA levels. Although additional clinical studies are needed to confirm the suggested cutoff for TDA, our data indicate significantly lower plasma drug levels of RIF at TDAs of Ͻ1.5, in accordance with a previous study, where an association with a lower degree of sputum smear conversion was observed (9) . A strength of the current study is the precision analysis of the TDA assay, as high intra-and interassay variabilities may potentially limit useful applications. Even if the TDA assay variability rarely affects clinical decisions regarding dose adjustments, we recommend that until a refined TDA method is developed focusing on the initial bacterial inoculum, samples taken before dose adjustment should be reanalyzed together with the follow-up sample. It is also worth considering an additional TDA sample 6 h after drug intake to identify patients with delayed peak RIF levels (12) . A further optimization of the TDA assay could include the M. tuberculosis isolate of each patient to get a more precise measurement of the ratio between the peak drug levels and the individual MICs (9); but, method variability and potential delays would then need to be thoroughly evaluated. In conclusion, patients with plasma levels of rifampin lower than 8 mg/liter had low TDA values. Our data support the use of TDA as an indicator for low rifampin exposure in settings where LC-MS methods are not available but TB culture facilities are. Further studies are needed to establish TDA as a therapeutic management tool in TB treatment.
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